Abstract: Embodiments of negative pressure wound therapy systems, apparatuses, and methods for operating the systems and apparatuses are disclosed. In some embodiments, the apparatus includes a negative pressure source, a connector port, at least one switch, and a controller. The negative pressure source is connected through the connector port to either (i) a wound dressing having a canister configured to store fluid aspirated from the wound or (ii) a wound dressing without a canister between the connector port and the wound dressing. The controller determines, based on a signal received from the at least one switch, whether the canister is positioned in the fluid flow path and adjusts one or more operational parameters of negative pressure wound therapy based on the determination. The switch is activated by the connection of either the canister or canisterless wound dressing to the apparatus.

Abstract: The present application relates to treating and/or preventing breast cancer, including locally advanced or metastatic, ER+, HER2? breast cancer, in a subject in need of treatment, comprising administering a compound of Formula (I), or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate, polymorph, isotopic derivative, or prodrug thereof, wherein R1, R2, R3, R4, m, and n are defined herein.

Abstract: The present application relates to treating and/or preventing prostate cancer, including metastatic and/or castrate-resistant prostate cancer, in a subject in need of treatment having particular somatic AR tumor biomarker status, comprising administering a compound of Formula (I), or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate, polymorph, isotopic derivative, or prodrug thereof, wherein R1, R2, R3, X1, X2, X3, X4, and n are defined herein.

Abstract: The present disclosure provides intelligent lighting control systems.

Abstract: Described herein are processable compositions comprising at least one moiety that is processable in its free form. Also described herein are compositions and methods for the treatment of ocular diseases or disorders including glaucoma, blepharitis, ocular inflammation, diabetic macular edema, posterior inflammation, anterior inflammation, macular degeneration (e.g., wet macular degeneration (AMD) or dry AMD), post-cataract surgery, and retinal vein occlusion. Said compositions and methods comprise steroids and prostaglandins which demonstrate anti-inflammatory activity, intraocular pressure (IOP) lowering, and/or other desirable activities. Injection of said compositions in the eye provides therapeutic benefit to patients suffering from ocular disorders.

Abstract: The disclosure features polymorphs of a prodrug dimer of dexamethasone linked at the 21-C and 21?-C carbons via a carbonate-triethylene glycol-carbonate linker. Also disclosed are pharmaceutical compositions and articles comprising said polymorphs, and the use thereof in the treatment of a disease or condition, e.g. via the extended or controlled release of dexamethasone from said articles.

Abstract: Described herein are processable compositions comprising at least one moiety that is processable in its free form. Also described herein are compositions and methods for the treatment of ocular diseases or disorders including glaucoma, blepharitis, ocular inflammation, diabetic macular edema, posterior inflammation, anterior inflammation, macular degeneration (e.g., wet macular degeneration (AMD) or dry AMD), post-cataract surgery, and retinal vein occlusion. Said compositions and methods comprise steroids and prostaglandins which demonstrate anti-inflammatory activity, intraocular pressure (IOP) lowering, and/or other desirable activities. Injection of said compositions in the eye provides therapeutic benefit to patients suffering from ocular disorders.

Abstract: Provided herein are compositions and methods for treating and preventing malaria. The vaccine of the invention is directed to the protein encoded by the PF3D7_1134300 gene, or fragments of the protein, which are Pf Erythrocyte Membrane and Merozoite Antigenl (PfEMMAI). Exemplary fragments include Fragment 1, Fragment 2, or a C-terminal fragment of PfEMMAI.

Abstract: A multi-way circuit having a plurality of base modules may be used in multi-way schemes for lighting control devices. The multi-way circuit may operate with a controller and the base modules of a lighting control system to provide a fully functional, multi-way toggle circuit, even when the switches installed in the base module are not paired or in their off modes. The multi-way toggle circuit can be defined as follows: if any button in the circuit is pressed (indicating a desire to change the load state), then the load toggles its state between on and off.

Abstract: Methods and systems for recovering naphtha blend stock from hydrocarbons produced in a fluid catalytic cracking (FCC) process. In particular, the disclosure concerns gas plants for an FCC process, wherein the gas plant uses a dividing wall column. The dividing wall column essentially performs the functions that are performed in a traditional FCC gas plant by three different columns, namely, a primary absorber, a stripper, and a debutanizer.

Abstract: The present invention discloses an adjuvant treatment of node-positive, early stage, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2?) breast cancer comprising administering an effective amount of an endocrine therapy in combination with an effective amount of abemaciclib or a pharmaceutically acceptable salt thereof.

Abstract: A dual-optical displacement sensor system includes a scanner including a first and second scanner head including optical displacement sensors providing a first and second beam having a first optical axis (OA) and a second OA. A computing device or programmed circuit is coupled to receive time versus position data from measurements involving alignment target(s) including at least one knife edge pair including a first and second knife edge oriented in a first plane of the alignment target that is essentially perpendicular to the OAs positioned between the scanner heads for interacting with the beams, and implement at least one equation to analyze the data for determining a degree of alignment of the first and second OA. Using the degree of alignment, an algorithm is for automatic alignment of the OAs or assist instructions for a user alignment of the OAs that provides guiding steps for the user for the alignment.

Abstract: Described herein are processable compositions comprising at least one moiety that is processable in its free form. Also described herein are compositions and methods for the treatment of ocular diseases or disorders including glaucoma, blepharitis, ocular inflammation, diabetic macular edema, posterior inflammation, anterior inflammation, macular degeneration (e.g., wet macular degeneration (AMD) or dry AMD), post-cataract surgery, and retinal vein occlusion. Said compositions and methods comprise steroids and prostaglandins which demonstrate anti-inflammatory activity, intraocular pressure (IOP) lowering, and/or other desirable activities. Injection of said compositions in the eye provides therapeutic benefit to patients suffering from ocular disorders.

Abstract: Some embodiments of the present invention comprise a method, system, and/or computer program product for a publish/subscribe messaging system. A processor identifies a subscriber of a pub/sub messaging system. The processor retrieves a stored encrypted key for the identified subscriber of the pub/sub messaging system. The processor communicates the retrieved encrypted key to a user selected from a group comprising a publisher of the pub/sub messaging system and the identified subscriber of the pub/sub messaging system. The processor implements end-to-end encryption of messages of the pub/sub messaging system based on key-groups.

Abstract: The disclosure features dexamethasone prodrug dimers of dexamethasone and pharmaceutical compositions thereof useful for, e.g., the extended release of a drug and for the treatment of a disease or condition.

Abstract: The invention relates to a liquid crystal mixture characterised in that it comprises one or more photoreactive mesogens of formula I wherein the parameters and groups occurring are defined as indicated in claim 1, to a process for the fabrication of liquid crystal displays using these liquid crystal mixtures and to a liquid crystal display obtainable by this process. The invention further relates to new compounds of formula I.

Abstract: A dividing wall column or a pair of conventional columns can be used to separate an unstabilized naphtha stream to produce an aromatics-free light naphtha stream as a feed for a catalytic cracking unit for olefins production.

Abstract: A dividing wall column is used in an alkylation process flow scheme to fractionate an alkylate reactor effluent to produce an iso-butane-rich stream as a recycle feed for the alkylation reactor while also separating iso-butane, normal butane and alkylate as separate product streams depending on the reactor effluent composition. In an optional embodiment, the scheme may contain propane.

Abstract: The present disclosure provides intelligent lighting control systems.

Abstract: The disclosure features pharmaceutical compositions formed from prodrug dimers for the extended delivery of a drug and for the treatment of a disease or condition.